Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health BDET Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentModa HealthPolicy N/A

    Balloon Dilation of the Eustachian Tube

    Customize your policy alerts

    Sign up for all Moda Health policy alerts

    Know when Moda Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Moda Health coverage, medical necessity criteria, exclusions, required documentation, and coding for balloon dilation of the eustachian tube (BDET) in adults; applies to providers requesting prior authorization for members.

    Policy Summary
    PayerModa Health
    PolicyBalloon Dilation of the Eustachian Tube (BDET)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateFeb 1, 2026
    Last ReviewJan 28, 2026
    Next Review DateFeb 1, 2026
    Key ActionSubmit prior authorization with chart notes and documentation of abnormal tympanogram or tympanic membrane abnormality.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥ 3 monthsminimum symptom duration required for consideration
    ≥ 18 yearsminimum patient age for coverage
    Type B or Cabnormal tympanogram types required
    4 codescovered CPT/HCPCS codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1/2021
    policy start

    Coverage and Medical Necessity Criteria

    Initial therapy (medical necessity)

    Covered when ALL of the following are met:

    Age and duration

    • Symptom specifics: Presence of aural fullness and pressure; symptoms are continuous rather than episodic (not limited to barochallenge); patient is NOT diagnosed with patulous ETD; other causes of aural fullness (e.g., TMJ disorder, extrinsic obstruction, superior semicircular canal dehiscence, endolymphatic hydrops) have been ruled out; patient has not previously had balloon dilation of the eustachian tube (BDET)

      Enumerated symptom and exclusion requirements.

    Diagnostic findings: Documentation of a completed comprehensive diagnostic assessment with ALL of: abnormal tympanogram (Type B or C) AND abnormal tympanic membrane (retracted membrane, effusion, perforation, or other abnormality on otoscopy)tympanogram = Type B or C

    Policy specifies required diagnostic test results.

    Medical management failure (if applicable): Failure to respond to medical management of co-occurring conditions when applicable (examples: allergic rhinitis/rhinosinusitis including 4–6 weeks of nasal steroid if indicated; laryngopharyngeal reflux treated with proton pump inhibitor or antacid)

    Policy requires documentation of medical management failure when applicable.

    Demonstrated reversibility: Reversibility of ETD demonstrated by either patient-reported ability to relieve pressure with a Valsalva maneuver OR Valsalva maneuver produces temporary improvement to a Type A tympanogram

    Policy lists Valsalva-based demonstration of reversibility.

    Balloon dilation of the eustachian tube (BDET) is NOT medically necessary for indications outside of the specific coverage criteria listed in this policy. The procedure is also specifically designated as investigational for repeat BDET and for any other uses not covered by the stated medical necessity criteria.

    Contraindications to balloon dilation include patients with extrinsic reversible or irreversible causes of eustachian tube dysfunction. Examples include, but are not limited to: enlarged adenoid pads, history of radiation therapy to the nasopharynx, craniofacial syndromes (including cleft palate spectrum), nasopharyngeal mass or skull base neoplasm, and neoplasms causing extrinsic obstruction of the eustachian tube. Additional contraindications listed are patulous eustachian tube dysfunction, aural fullness with normal exam and tympanogram, and chronic and severe atelectatic ears (retracted tympanic membrane).

    Repeat balloon dilation of the eustachian tube is considered investigational and not medically necessary. Requests for repeat BDET do not meet coverage criteria under this policy.

    Any indication that does not meet the explicit medical necessity criteria set forth in this policy is considered not medically necessary and will not be covered.

    Procedure and Diagnosis Codes

    Covered CPT/HCPCS CodesCPT | HCPCSCovered
    69705Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral.
    69706Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral.
    69799Unlisted procedure, middle ear.
    C9745Nasal endoscopy, surgical; balloon dilation of eustachian tube
    CPT/HCPCS Codes NOT coveredmixedNot Covered
    No codes listed
    Appendix diagnosis codesICD-10
    No codes listed

    Prior Authorization, Documentation, and Denial Risk

    Prior Authorization

    Prior authorization must include chart notes and abnormal tympanogram/tympanic membrane documentation; list covered codes

    Prior authorization is required and must include chart notes plus documentation of an abnormal tympanogram or tympanic membrane abnormality. Covered procedure codes to reference on the authorization are CPT 69705, 69706, 69799 and HCPCS C9745.

    • Submit chart notes with history documenting diagnosis and treatment of chronic ETD and otoscopy findings.
    • Provide tympanogram showing Type B or C OR documentation of tympanic membrane abnormality.
    • Reference covered codes: 69705, 69706, 69799, C9745 on the authorization request.
    Step Therapy

    Document failure of medical management for co-occurring conditions when applicable

    When applicable, document that the member failed to respond to medical management of co-occurring conditions before BDET is performed (examples provided by the policy).

    Clinical Background

    Eustachian tube dysfunction (ETD) presents with symptoms such as muffled hearing, aural fullness, ear popping, tinnitus, or balance problems and can progress to hearing loss or chronic middle ear disease. Balloon dilation of the eustachian tube (BDET) is a minimally invasive transnasal procedure intended to increase patency of the cartilaginous portion of the eustachian tube and reduce inflammation by brief balloon inflation. Clinical selection for BDET relies on symptom duration, objective findings (for example, abnormal tympanogram Type B or C and abnormal tympanic membrane on otoscopy), and demonstration of reversibility (such as relief with a Valsalva maneuver).

    Key Definitions

    Obstructive Eustachian Tube Dysfunction (OETD) — definition and common symptoms
    DefinitionInability of the eustachian tube to ventilate and protect the middle ear, presenting with symptoms such as aural fullness, pressure, muffled hearing, ear popping, tinnitus, or balance problems; BDET targets chronic obstructive dysfunction of the cartilaginous portion of the ET.
    Typical symptomsAural fullness and pressure; muffled hearing or hearing loss; ear popping; tinnitus; balance problems.
    Clinical significanceLong‑term ETD can lead to hearing loss, cholesteatoma, or chronic suppurative otitis media and can significantly impair quality of life.
    Target of BDETMinimally invasive dilation of the cartilaginous eustachian tube via transnasal balloon to increase patency and reduce inflammation.
    Reversible ETD demonstrated by Valsalva — clinical reversibility criterion
    Clinical reversibility by Valsalva (definition)

    Policy Revision History

    2026-02-01Effective dateLatest

    Policy effective date set to 2026-02-01 reflecting the annual review with no clinical changes

    2026-01-28Last review

    Last review completed on 2026-01-28 (annual review noting no changes)

    2025-02-01Effective date
    Policy Summary
    PayerModa Health
    PolicyBalloon Dilation of the Eustachian Tube (BDET)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateFeb 1, 2026
    Last ReviewJan 28, 2026
    Next Review DateFeb 1, 2026
    Key ActionSubmit prior authorization with chart notes and documentation of abnormal tympanogram or tympanic membrane abnormality.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProcedure and Diagnosis CodesPrior Authorization, Documentation, and Denial RiskClinical BackgroundKey DefinitionsPolicy Revision History
    • Allergic rhinitis/rhinosinusitis: trial of medical therapy including 4–6 weeks of a nasal steroid if indicated.
    • Laryngopharyngeal reflux: trial of proton pump inhibitor or antacid therapy.
    Documentation Required

    Information required with prior authorization: chart notes, history, treatment, and tympanic membrane/tympanogram documentation

    Include chart notes with history documenting the diagnosis and prior treatments for chronic eustachian tube dysfunction, plus documentation of tympanic membrane abnormality and/or an abnormal tympanogram.

    • History and treatment details for chronic ETD.
    • Otoscopy findings showing tympanic membrane abnormality (retraction, effusion, perforation, or other abnormality).
    • Tympanogram result demonstrating Type B or C when available.
    Denial Risk

    Denial triggers: missing medical necessity elements or contraindications

    Requests may be denied if all medical necessity criteria are not met; common denial triggers include insufficient symptom duration, patient age under 18, lack of abnormal tympanogram or tympanic membrane findings, prior BDET, or listed contraindications.

    • Symptoms less than three months in duration.
    • Patient is younger than 18 years.
    • No documentation of abnormal tympanogram (Type B or C) or abnormal tympanic membrane on otoscopy.
    • Prior balloon dilation of the eustachian tube (BDET) already performed.
    • Presence of contraindications (e.g., extrinsic causes such as enlarged adenoids, history of nasopharyngeal radiation, craniofacial syndromes, nasopharyngeal mass, patulous ETD, chronic severe atelectatic ears).
    Patient reports relief of symptoms with a Valsalva maneuver or Valsalva produces temporary normalization of pressure (e.g., improvement toward a Type A tympanogram).
    How assessedDocumented patient report of symptom relief with Valsalva or observed temporary improvement in tympanometry following Valsalva.
    Role in coverageReversibility demonstrated by Valsalva is an acceptable demonstration of ETD reversibility per policy criteria for consideration of BDET.

    Requirements demonstrating reversibility of eustachian tube dysfunction were added effective 2025-02-01

    2024-02-01Effective date

    Contraindication updated to add 'skull base neoplasm' effective 2024-02-01

    2023-02-01Effective date

    Annual review completed with no changes effective 2023-02-01

    2022-02-01Effective date

    Annual review completed with no changes effective 2022-02-01

    2021-04-15Effective date

    CPT code C9745 was added to the criteria effective 2021-04-15

    2021-01-27Policy origin

    Policy originated with new criteria on 2021-01-27 (date of origin 1/2021)